Author Archives: Danielle Park

Innate Immunotherapeutics is a small Australian biotech company who’s main drug is an investigational treatment for multiple sclerosis.  New York House Rep Chris Collins is a board member and was Innate’s largest shareholder with a position valued at over $45 … Continue reading →

As fresh-faced CNBC hosts come and go, a few guests have decades of real life market experience. Fewer still are independents free to call conditions as they seem them, unconstrained by their corporate sales targets for proprietary financial products and … Continue reading →

The Bank of International Settlements (BIS) is a board made up of 60 different central bank heads, that meets bi-monthly in Basel, Switzerland and bizarrely issues reports where they talk about central bankers (ie., themselves) in the third person.   Rather … Continue reading →